Visual acuity outcome after intravitreal Bevacizumab injection in retinal vein occlusion

Retinal vein occlusion causes sudden visual loss and macular edema.Visual improvement after intravitreal Bevacizumab in recent years is argued in this study. To define the Bevacizumab effect on visual outome in retinal vein occlusion.
All attendants who had a diagnosis of retinal vein occlusion after ophthalmic examination enrolled in this study. The logarithm of the vision set, before 1.25 mg Bevacizumab injected intravitrealy was compared with postoperative visual acuity of log Mar of 1, 3 and 6 months after injection. The possible side effects of intravitreal injection of Bevacizumab ,after 1, 3 and 6 months were recorded. The Cross Kalvalys ,Wilcoxon and Friedman rank correlation coefficients of α≤0.05 were assessed in study.
The mean age of 39 patients was 60.70 ± 10.9 years. The mean disease duration was 2.29 ± 2.72 months. There was statistically significant difference in mean Log Mar visual acuity regarding the duration of time. Mean visual acuity before injection was 1.58 ± 0.81, a month after the injection 0.93 ± 0.77, three months after the injection 1.16 ± 0.97, and six months after injection, 1.27 ± 1.
The Bevacizumab has significant role in improving vision in patients with retinal vein occlusion, although ocular complications after intraocular injection of Bevacizumab are far less than other similar approaches but few no responding occur which develop neovascular glaucoma.